ArticleJournal of radiosurgery and SBRT2025
Stereotactic body radiotherapy for unresectable or locally recurrent pancreatic cancer: A single centre experience.
Article in Journal of radiosurgery and SBRT, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To refer our experience with stereotactic body radiotherapy (SBRT) in patients with pancreatic cancer. Materials and methods: 45 Patients with unresectable or locally recurrent pancreatic cancer after primary surgery, were submitted to SBRT. Toxicities were graded according to CTCAE version 5. Statistical analysis was performed by the Kaplan-Meier method. Results: The characteristics of the patients were median age 70 years (range, 46-84 years), median KPS 90% (range, 80-90%). Six patients had recurrent cancer after surgery, the other 39 patients were unresectable. Median radiation dose was 35 Gy (range, 27-40 Gy) delivered in 5 fractions. Simultaneous integrated boost with median dose of 35 Gy (range, 30-45 Gy) was given in 7 patients.After median follow-up of 10 months (range, 3-61 months) median local control was 10 months (range,5-15 months) and 49% (±8%) at 1-year. Median overall survival (OS) was 10 months (range,7-14 months), 38 % (±7%) at 1 year. Type of radiological response statistically significant influenced LC and OS, stage only LC in non-significant way. Clinical response was obtained in 12 of 36 (33%) cases. Median Numeric Rating Scale (NRS) was 7 (range, 4-8) before radiotherapy and 1 (range, 0-5) post SBRT. Acute G1-2 gastrointestinal toxicities were registered in 15% of patients, no late toxicities were found. Conclusion: In our series we obtained a good local palliation with SBRT that is a safe and effective treatment option. Higher doses could be administered in selected patients to obtain better response to treatment that is correlated with LC and OS.
Indexed as
Identifiers
40476277PMC12136683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.